Goldman Sachs
NRXP icon

Goldman Sachs’s NRX Pharmaceuticals NRXP Stock Holding History

Goldman Sachs’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,162
Closed -$16K – 6181
2022
Q3 		$16K Sell
2,162
-89
-4% -$600 ﹤0.01% 5968
2022
Q2 		$14K Buy
2,251
+122
+6% +$1.6K ﹤0.01% 6226
2022
Q1 		$52K Buy
2,129
+167
+9% +$5.43K ﹤0.01% 6264
2021
Q4 		$94K Buy
+1,962
New +$142K ﹤0.01% 6149

Other funds holding NRXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Goldman Sachs's NRXP Position: Q4 2022 in Review

Goldman Sachs sold out of NRX Pharmaceuticals (NRXP) in Q4 2022, closing a stake of 2,162 shares — an estimated $16K sold.

Goldman Sachs first reported a position in NRXP in Q4 2021 and held it in 4 quarters. The position peaked at $94K in Q4 2021. 33 funds tracked by Wall St. Rank hold NRXP as of Q4 2022.

  • Goldman Sachs reported no remaining NRX Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Goldman Sachs sold 2,162 NRX Pharmaceuticals shares in Q4 2022, an estimated $16K.
  • Goldman Sachs first reported a position in NRX Pharmaceuticals in Q4 2021 and held it in 4 quarters.
  • Goldman Sachs's NRX Pharmaceuticals position peaked at $94K in Q4 2021.
  • 33 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.